DSIP vs PT-141 (Bremelanotide)

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

DSIP

Delta Sleep-Inducing Peptide is a neuropeptide that promotes delta wave sleep, the deepest and most restorative phase of the sleep cycle.

Full details →

PT-141 (Bremelanotide)

PT-141, also known as Bremelanotide, is a synthetic peptide analog of alpha-melanocyte-stimulating hormone. It is the only FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women.

Full details →

Side-by-Side Comparison

Aspect	DSIP	PT-141 (Bremelanotide)
Dose Range	100 mcg–300 mcg	1.8 mg
Frequency	1x daily	Less than daily
Cycle Length	1–6 weeks	4–12 weeks
Route	subcutaneous	subcutaneous
Mechanism	Modulates sleep-wake cycles by affecting sleep spindles and delta rhythms. May also influence stress hormones and have analgesic properties.	PT-141 activates melanocortin receptors (MC3R and MC4R) in the central nervous system, particularly in areas associated with sexual arousal. Unlike PDE5 inhibitors, it works through the nervous system rather than the vascular system.
Typical Dosage	Typical dosing: 100-300mcg administered 30 minutes before sleep. Some protocols use it cyclically.	FDA-approved dose: 1.75mg administered subcutaneously at least 45 minutes before anticipated sexual activity. Not to be used more than once within 24 hours or more than 8 times per month.
Administration	Subcutaneous or intramuscular injection before bedtime. Some users report better results with cyclical use.	Subcutaneous injection in the abdomen. Available as Vyleesi (commercial product). Research use may involve different dosing protocols.
Side Effects	May cause grogginess upon waking, vivid dreams, or temporary headaches.	Common side effects include nausea (40% of users), flushing, headache, and injection site reactions. Transient blood pressure increases may occur.
Best For	Recovery & Healing Sleep Quality	Recovery & Healing